Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -4,7 +4,7 @@
4	4
5	5	= Company overview =
6	6
7		-Headquartered in Mumbai, Alkem Laboratories is one of India’s foremost global pharmaceutical company. The Company is engaged in the development, manufacture and marketing of pharmaceuticals with operational footprints across 40+ countries. In India, it has a formidable presence in several therapy segments and consistently features amongst the top ten pharmaceutical companies.
	7	+Headquartered in Mumbai, Alkem Laboratories (NSE:ALKEM) is one of India’s foremost global pharmaceutical company. The Company is engaged in the development, manufacture and marketing of pharmaceuticals with operational footprints across 40+ countries. In India, it has a formidable presence in several therapy segments and consistently features amongst the top ten pharmaceutical companies.
8	8
9	9	Steered by its industry experience of over four decades, Alkem offers high-quality branded generics, generic drugs, active pharmaceutical ingredients and nutraceuticals. The Company’s product portfolio features over 800 brands encompassing all major therapeutic segments.
10	10
...	...	@@ -45,6 +45,8 @@
45	45	|(% style="width:136px" %)California|(% style="width:122px" %)1|(% style="width:396px" %)Active Pharmaceutical Ingredients (APIs)
46	46	|(% style="width:136px" %)St. Louis (Missouri)|(% style="width:122px" %)1|(% style="width:396px" %)Formulations - Liquids, Nasal Sprays, Semi-solids, Solids
47	47
	48	+{{putFootnotes/}}
	49	+
48	48	= Industry Overview =
49	49
50	50	The global pharmaceutical industry is one of the largest and the oldest industries in the world. As per a research report by the IQVIA Institute for Human Data Science, the global pharmaceutical industry is estimated to be US$ 1.25 trillion (at invoice level) in 2019 and is expected to grow at a compounded annual growth rate (CAGR) of 3-6% over 2020-2024 to touch US$ 1.6 trillion in 2024. This growth would primarily be driven by ageing and rising population, improvements in purchasing power, access to quality healthcare by poor and middle-class families worldwide and innovation and advancement in rare and specialty diseases including biologics, nucleic acid therapies and cell therapies. However, adoption of price control policies, tightening of regulations by governments in key markets and loss of exclusivity of large brands would offset some part of this growth.{{footnote}}https://www.alkemlabs.com/pdf/annual-report/Annual_Report_2019-20-2.pdf{{/footnote}}